Table 2 Characteristics of researches on the feasibility of DRA in cardiac catheterization
Year | First author | Country | Study design | Access site | Number (n) | Age (Mean, y) | Male (%) | Success rate (%) | ACS (%) | PCI (%) | ≥6F Sheath (%) | Right (%) | Diameter (Mean, mm) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2017 | Kiemeneij F [21] | Netherlands | Case-series | DRA | 70 | 68 | 79 | 89 | NA | 36 | 58 | 0 | NA |
2018 | Soydan E [22] | Turkey | Case-series | DRA | 54 | 59.3 | 80 | 100 | 31.4 | 8.5 | 100 | 0 | NA |
2018 | Valsecchi O [23] | Italy | Case-series | DRA | 52 | 68 | 82 | 90 | 9.6 | 48.1 | 98.1 | 84.6 | 2.22 |
2018 | Kim Y [24] | South Korea | Retrospective | DRA | 150 | 65.9 | 71.2 | 93.3c | 43.9 | 27.3 | 100 | 0 | 2.57 |
2018 | Lee JW [25] | South Korea | Prospective | DRA | 200 | 66.1 | 66 | 95.5 | 31 | 43.5 | 33.0 | 0 | 2.41a/2.36b |
2018 | Ziakas A [26] | Greece | Case-series | DRA | 49 | 64 | 63.3 | 91.8c | 24.5 | 18.2 | 79.6 | 100 | NA |
2018 | Babunashvili A [27] | Russia | Retrospective | DRA | 1320 | 63.2 | 68.1 | 99.7 | NA | 47.6 | 45.6 | 80.9 | 2.13 |
2018 | Al-Azizi KM [28] | America | Case-series | DRA | 61 | 70 | 75.4 | 98.4 | 73.7 | 55.7 | 86.9 | 0 | NA |
2018 | Flores EA [29] | Georgia | Retrospective | DRA | 200 | 64 | 69 | 95.5 | 51.0 | 28 | NA | 85 | NA |
2019 | Mizuguchi Y [30] | Japan | Retrospective | DRA | 228 | 71.1 | 71.1 | 100 | NA | 33.8 | 29 | 88.6 | 2.4 |
2019 | Norimatsu K [31] | Japan | Retrospective | DRA | 74 | 70 | 78 | 92 | 8 | 40 | 23 | 84 | 2.6 |
2019 | Wretowski D [32] | Poland | Case-series | DRA | 218 | 68 | 65.14 | 89.4 | 19.72 | 36.2 | 56.9 | 51 | NA |
2019 | Gasparini GL [33] | Italy | Prospective | DRA | 47 | 67.8 | 75.6 | 82.9 | NA | 100 | 100 | NA | NA |
2019 | Uddin MJ [34] | Bangladesh | Case-series | DRA | 200 | 52.3 | 75 | 98.5 | NA | 36 | NA | 100 | NA |
2019 | Amin MR [35] | Bangladesh | Case-series | DRA | 100 | NA | NA | 98 | NA | NA | NA | NA | NA |
2020 | Yu WW [36] | China | Case-series | DRA | 92 | 69 | 62.0 | 95.7 | 48.9 | 42.4 | 100 | 95.7 | 1.71 |
2017 | Kaledin A [37] | Russia | Retrospective | DRAd | 2 696 | NA | NA | 97.7 | NA | NA | 99.6 | NA | 2.4 |
TRA | 2781 | NA | NA | 96 | NA | NA | 99.3 | NA | 2.7 | ||||
2018 | Coughlan JJ [38] | Iran | Non randomized control study | DRA | 47 | 61 | 83 | 100 | NA | 0 | 10.6 | 0 | NA |
TRA | 47 | 61.8 | 74.5 | 100 | NA | 0 | 17.1 | 0 | NA | ||||
2018 | Roghani-Dehkordi F [39] | Iran | Cross-sectional study | DRA | 235 | NA | 76.5 | 94.1 | NA | 28.9 | NA | NA | NA |
Trans-palmar | 175 | NA | 76 | 90.8 | NA | 18.2 | NA | NA | NA | ||||
2018 | Koutouzis M [40] | Greece | Randomized control study | DRA | 100 | 63.8 | 74 | 70 | NA | NA | NA | NA | NA |
TRA | 100 | 62.8 | 77 | 98 | NA | NA | NA | NA | NA | ||||
2018 | Gajurel RM [41] | Nepal | Prospective study | DRA | 82 | 57.7 | 58.5 | 97.6 | NA | 24.3 | 65.8 | 100 | NA |
TRA | 82 | 57.2 | 53.6 | 96.4 | NA | 39.0 | 71.9 | 100 | NA | ||||
2019 | Aoi S [42] | America | Retrospective | DRA | 202 | 69.2 | 64.9 | 99.5 | NA | 44.6 | NA | 88.1 | NA |
TRA | 206 | 68.8 | 62.6 | 99 | NA | 44.7 | NA | 90.8 | NA | ||||
2019 | El Tahaan M [43] | Egypt | Non randomized control study | DRA | 50 | 53.42 | 70.0 | 92 | NA | 36 | NA | 44 | NA |
TRA | 50 | 54.07 | 72.0 | 100 | NA | 34 | NA | 44 | NA | ||||
2019 | Mori S [44] | Japan | Prospective | DRA | 43 | NA | NA | 92.9 | NA | 35.9 | NA | NA | NA |
TRA | 53 | NA | NA | 94.3 | NA | 41.1 | NA | NA | NA | ||||
2019 | Vefalı V [45] | Turkey | Non randomized control study | DRA | 102 | 60.89 | 70.6 | 95.1 | NA | 23.53 | NA | 15 | 2.05 |
TRA | 103 | 59.84 | 68 | 96.1 | NA | 24.27 | NA | 18 | 2.32 |